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Abstract
 
Continuous lymphocyte recirculation between blood and lymphoid tissues forms a basis for the
function of the immune system. Lymphocyte entrance from the blood into the tissues has been
thoroughly characterized, but mechanisms controlling lymphocyte exit from the lymphoid tis-
sues via efferent lymphatics have remained virtually unknown. In this work we have identified
mannose receptor (MR) on human lymphatic endothelium and demonstrate its involvement in
binding of lymphocytes to lymphatic vessels. We also show that the binding requires L-selec-
tin, and L-selectin and MR form a receptor–ligand pair. On the other hand, L-selectin binds to
peripheral lymph node addressins (PNAds) on high endothelial venules (HEVs) that are sites
where lymphocytes enter the lymphatic organs. Interestingly, MR is absent from HEVs and
PNAds from lymphatic endothelium. Thus, lymphocyte L-selectin uses distinct ligand mole-
cules to mediate binding at sites of lymphocyte entrance and exit within lymph nodes. Taken
together, interaction between L-selectin and MR is the first molecularly defined mechanism
mediating lymphocyte binding to lymphatic endothelium.
 
Key words: lymphatics • lymphocyte recirculation • cancer metastasis • endothelium • 
lymph node
 
Introduction
 
The majority of lymphocytes extravasate into the lymph
nodes via specialized vessels called high endothelial venules
 
(HEVs)
 
*
 
. The molecular mechanisms mediating lympho-
cyte entrance into the lymph nodes via HEVs are rather
well known and the multistep interaction between lym-
phocyte surface molecules and their counter-receptors on
endothelium are thoroughly characterized (1–3). For ex-
ample, L-selectin is crucial for lymphocytes to recognize
and roll on the luminal surface of peripheral lymph node
HEVs. There it uses peripheral lymph node addressins
(PNAds) as its endothelial cell counterpart (4). Rolling is
followed by an activation step regulated by the function of
certain chemokines and their receptors. Thereafter, firm
adhesion is mediated by integrins and their Ig–superfamily
ligands on endothelium. However, integrins can also func-
tion without a preceding rolling step, for example, in
smaller capillaries, where the shear is low (1–3).
A small part of incoming lymphocytes enter the nodes
via afferent lymphatics together with antigens and other
types of hematopoietic cells such as dendritic cells, mac-
rophages, and granulocytes. However, only lymphocytes
are able to leave the nodes via efferent lymphatic system by
first traversing the sinusoidal endothelium and then enter-
ing the efferent lymphatic vessel (5–7). To maintain the
homeostasis in the lymph node the numbers of entering
and exiting lymphocytes need to be well in balance. In ad-
dition to being of fundamental importance in normal lym-
phocyte recirculation, the lymphatics also regulate seeding
 
of metastasizing cells in those 
 
 
 
50% of cancers, which use
this type of vessels for spreading.
At the moment, a few molecules present on lymphatic
endothelium have been characterized. Those include D6,
 
a 
 
 
 
-chemokine receptor (8), and vascular endothelial
growth factor receptor (VEGFR)-3 that seems to be criti-
cal for normal lymphangiogenesis (9). Moreover, an en-
docytic receptor for hyaluronan (LYVE-1) is expressed
rather dominantly on lymphatic endothelium (10) and
podoplanin, first identified as a glomerular podocyte mem-
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brane mucoprotein in kidney, has been successfully used as
a lymphatic endothelial marker (8, 11). However, nothing
is known about the molecules mediating lymphocyte exit
from the tissues via lymphatics. Therefore, our aim in this
work was to characterize such molecules in human lym-
phatic vessels.
 
Materials and Methods
 
Production of Monoclonal Antibodies.
 
Balb/c mice were immu-
nized to footpads four times at 1 wk intervals with incomplete
Freund’s adjuvant containing suspension made from efferent lym-
phatic vessels excised from human lymph nodes. The popliteal
lymph node lymphocytes of the immunized mice were fused
with Sp2/0 myeloma cells. Hybridoma supernatants were prima-
rily tested on frozen sections of human lymph nodes using immu-
noperoxidase staining and 3-155 antibody (IgG) was selected for
further studies based on its staining of lymphatic endothelium.
 
Immunostainings.
 
Immunoperoxidase stainings were per-
formed as described previously (12). In brief, acetone fixed 6-
 
 
 
m
frozen sections from different human tissues (lymph nodes, ap-
pendix, bronchus, cerebellum, epididymis, oesophagus, heart,
small and large intestine, kidney, liver, lung, normal and psoriatic
skin, synovium, testis, and tonsil; procedures for tissue collection
were approved by the Local and National Boards of Medicolegal
Affairs in Finland) were stained with hybridoma supernatants of
3-155 or negative class matched control antibody (3G6 against
chicken T cells; reference 12) and lymph nodes also with
MECA-79 (rat IgM) against PNAds (a gift from E. Butcher,
Stanford University, Stanford, CA; reference 13) followed by
peroxidase-conjugated rabbit anti–mouse Ig (1:40; Dako) or per-
oxidase-conjugated rabbit anti–rat Ig (1:100; Dako), respectively.
3,3-diaminobenzidine in PBS containing 0.03% hydrogen per-
oxide was used as a chromogen. Finally, the sections were coun-
terstained in hematoxylin (Sigma-Aldrich), dehydrated, cleared
in xylene, and permanently mounted in DePex (BDH Limited).
Results were analyzed independently by two individuals. To test
similarity between our new antibody and earlier known mannose
receptor (MR) antibody we used monoclonal anti–human MR
antibody (anti–hMR-Ab; Research Diagnostics, Inc.) at 1 
 
 
 
g/ml
and stained peripheral lymph nodes, tonsil, and liver samples in
parallel with both antibodies using the same protocol as de-
scribed above.
In double stainings of lymph node sections FITC-conjugated
3-155 (50 
 
 
 
g/ml) together with MECA-79 (10 
 
 
 
g/ml, anti-
PNAd) and goat polyclonal anti-VEGFR-3 (10 
 
 
 
g/ml VEGFR-3;
R&D Systems) were used. Tetramethyl rhodamine isothiocyan-
ate–conjugated rabbit anti–goat IgG (Zymed Laboratories) with
5% AB-serum and 5% normal mouse serum was the secondary
Ab for anti-VEGFR-3 and R-phycoerythrin–conjugated goat
anti–rat IgM (Southern Biotechnology Associates, Inc.) with 5%
AB-serum was the secondary Ab for anti-PNAds. After staining,
the samples were mounted with ProLong
 
®
 
 Antifade kit (Molecu-
lar Probes). Negative controls in this staining were FITC-conju-
gated anti–mouse V
 
 
 
4, TIB 146 (rat anti–mouse CD45, IgM;
American Type Culture Collection), and normal goat serum
(Vector Laboratories). In skin samples anti-VEGFR-3 (50 
 
 
 
g/ml)
was detected with FITC-conjugated anti–goat IgG (1:100;
Sigma-Aldrich) with 5% of AB-serum and 5% of normal mouse
serum and staining was enhanced with Alexa Fluor™ antifluores-
cein (goat IgG; Molecular Probes). Biotinylated 3-155 (50 
 
 
 
g/
ml) was detected with PE-conjugated streptavidin (Becton Dick-
 
inson). Normal goat serum and biotinylated 3G6 were used as
negative controls.
To detect the ligands for L-selectin, supernatant containing
human L-selectin-IgM chimera (extracellular part of human
L-selectin fused to Fc part of human IgM) was incubated on frozen
sections of human lymph nodes. The nonspecific binding sites
and reactivity towards IgM positive cells in the section were pre-
blocked (before adding L-selectin-IgM chimera) using normal
goat serum and goat anti–human IgM (Caltag). The bound L-selec-
tin-IgM was detected using biotinylated goat anti–human IgM
(Caltag) followed by streptavidin-horseradish peroxidase. The re-
action was visualized using NovaRed (Vector Laboratories). The
control sections were treated otherwise similarly but without ad-
dition of L-selectin IgM chimera.
For flow cytometric analyses, peripheral blood mononuclear
cells, thoracic duct lymphocytes, and peripheral blood-derived
monocytes were used. Peripheral blood mononuclear cells from
healthy volunteers were isolated by Ficoll-Hypaque gradient cen-
trifugation. Monocytes were isolated from buffy coats (Finnish
Red Cross) first by using Ficoll-Hypaque gradient centrifugation,
and then by selecting the adhesive cells after 2-h incubation at
 
 
 
37
 
 
 
C in complete medium which is RPMI 1640 containing 10
mM Hepes, 10% FCS, 4 mM 
 
L
 
-glutamine, 100 
 
 
 
g/ml strepto-
mycin, and 100 U/ml penicillin. Monocytes were activated for
24 h in complete medium supplemented with 50 ng/ml GM-
CSF. Thoracic duct lymphocytes were obtained from drainages
used to treat thoracic duct fistulae.
For staining, the cells were first incubated with 3-155 superna-
tant or anti-hMR-Ab (2 
 
 
 
g/ml) and then with FITC-conjugated
anti–mouse IgG (Sigma-Aldrich). Thereafter, the cells were fixed
in PBS containing 1% formaldehyde. 3G6 was used as a negative
control antibody. Samples were analyzed using flow cytometer
(FACScan™; Becton Dickinson).
 
In Vitro Adhesion Assay.
 
Two types of adhesion assays were
used. A “static” assay was developed to mimic the conditions of
lymphocyte binding to lymphatic endothelium within lymph
nodes in the absence of shear. The classic Stamper-Woodruff
binding assays were used to mimic the binding of bloodborne
cells to vascular endothelium in vessels under physiological shear.
In the static assays lymph node sections were first incubated
with 3-155, anti–L-selectin (Dreg-56), or control antibodies,
3G6 or anti-HLA ABC (HB-95; American Type Culture Col-
lection [50 
 
 
 
g/ml of all antibodies were used, if not indicated
otherwise]) and then overlaid with Ficoll-Gradient purified pe-
ripheral blood mononuclear cells (3
 
   
 
10
 
6
 
 cells per section). To
test whether there is subtype preference in lymphocyte binding
to lymphatic endothelium, lymphocytes were stained before the
assay with PE-conjugated anti-CD8 or anti-CD4 (both antibodies
were from Becton Dickinson). Alternatively, L-selectin negative
or positive lymphocytes selected using nonblocking antibody
Leu-8 (Becton Dickinson) against L-selectin and goat anti–
mouse IgG-coupled supermagnetic beads (MACS
 
®
 
; Miltenyi
Biotec) were used. These staining and isolation procedures do
not affect endothelial binding capacity of cells (17). Thereafter,
the sections were let to stay in static conditions for 15 min, fol-
lowed by 5 min of rotation at 60 rpm, and then again 15 min
without rotation at 7
 
 
 
C. Certain assays were performed under
constant rotation. However, static conditions were needed for
optimal binding to lymphatic endothelium. The adherent cells
were fixed in 1% glutaraldehyde.
The classical Stamper-Woodruff assays were done using the
same cell concentrations and antibody concentrations. The only
difference was that the cells were applied onto the section under 
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constant rotation (60 rpm) and let adhere for 30 min under these
nonstatic conditions.
The number of lymphocytes bound to sinusoidal (lymphatic)
endothelium (and to HEVs in certain assays) was counted single
blind under dark-field illumination in which setting the sinusoi-
dal vessels are easily recognizable. Epi-illumination was used to
detect bound CD4 and CD8 positive cells (their percentage in
the input population was assayed using flow cytometer). The re-
sults of the inhibition assays are presented as percentage of control
binding (the number of adherent cells/vessel in the presence of
control mAb defines 100% adherence).
 
Peptide Analyses.
 
The molecule recognized by 3-155 anti-
body was purified from human lymph node lysate (lysis buffer:
150 mM NaCl, 10 mM Tris-base, 1.5 mM MgCl
 
2, 
 
1% NP-40, 1
mM PMSF, and 1% aprotinin) using CnBr-Sepharose 4B (Am-
ersham Pharmacia Biotech) columns coupled with 3-155 anti-
body (5 mg/ml beads) and a previously described protocol (14).
The columns were washed extensively with the lysis buffer and
the material bound to the 3-155 column was eluted with 50
mM triethylamine and lyophilized. The eluted material was
then subjected to SDS-PAGE analysis and silver staining. The
specific band was excised, reduced, alkylated, and digested with
trypsin (Promega) overnight at 
 
 
 
37
 
 
 
C as described previously
(15). The peptides were analyzed using PerSeptive Biosystems
Voyager DE-PRO mass spectrometer operated in the reflectron
delayed-extraction mode. Calibration of the spectrum was per-
formed internally by using autolysis products of trypsin or with
added calibration mixture 2 (PerSeptive BioSystems). Data base
search was performed by MS-Fit algorithm (prospector.ucsf.
edu/ucsfhtml3.2/msfit.htm) of the UCSF mass spectrometry fa-
cility.
 
Glycosidase Treatments.
 
NP-40 (1%) containing lysates from
GM-CSF activated monocytes and lymph nodes were treated
with 40 mU 
 
Vibrio cholerae
 
 neuraminidase (4 h; Dade Behring,
Inc.), 40 mU neuraminidase (4 h) plus 2 mU 
 
O
 
-glycanase
(overnight; Glyko, Inc.), and 10 mU 
 
N
 
-glycanase (overnight;
Glyko [reference16]). All incubations were done at 37
 
 
 
C and
control incubations were performed under similar conditions
without enzymes. Thereafter, the samples were run on SDS-
PAGE, blotted to nitrocellulose sheets, and probed with 3-155
antibody or a negative control antibody (3G6); both antibodies
were used at concentration of 2 
 
 
 
g/ml. Peroxidase-conjugated
rabbit anti–mouse Ig (1:1,000; Dako) was used as the second
stage reagent. Detection was performed using enhanced chemi-
luminescence system (Hybond-ECL; Amersham Pharmacia
Biotech).
 
Crossprecipitation Studies and Ligand Analyses.
 
Antibodies 3-155,
anti-hMR (HyCult Biotechnology), and 3G6 (neg co) were
loaded to protein A-Sepharose beads coupled to rabbit anti–
mouse Igs (Dako). These beads were used to immunoprecipitate
antigens from human lymph node lysates. The original and de-
pleted lysates were analyzed by SDS-PAGE and immunoblotting
using enhanced chemiluminescence (Amersham Pharmacia Bio-
tech) with anti-hMR as a primary Ab.
L-selectin-IgM chimera was loaded on protein A-Sepharose
beads coupled to goat anti–human IgM (Caltag). After washings,
these beads and the control beads without L-selectin chimera
were used to immunoprecipitate antigens from human lymph
node lysates. The resultant depleted lysates were analyzed by
SDS-PAGE and immunoblotting using enhanced chemilumines-
cence (Amersham Pharmacia Biotech). The intensity of the 3-155
bands was quantified using Microcomputer Imaging Device
(MCID; Imaging Research, Inc.).
 
Results
 
A New Antibody Detects a Molecule Mediating Lymphocyte
Binding to Lymphatics.
 
The molecular mechanisms in-
volved in lymphocyte exit are unknown. To identify mi-
gration-associated structures we produced monoclonal an-
tibodies against isolated efferent lymphatic vessels of human
lymph nodes. One of the antibodies (3-155) clearly stained
lymphatic endothelium both in afferent and efferent lym-
phatic systems (Fig. 1). This was confirmed by using a dou-
ble staining technique with an antibody against a known
lymphatic endothelial marker VEGFR-3. Remarkably,
3-155 did not stain HEVs that were brightly PNAd posi-
tive (Fig. 1).
To analyze whether the molecule recognized by 3-155
is involved in mediating lymphocyte binding to lymphatic
endothelium, a new adhesion assay was developed. This
was necessary, because lymphocytes under constant rota-
tion (normally used condition in a Stamper-Woodruff
type of assay) do not bind to lymphatic endothelium. If
static conditions are used lymphocytes effectively bind to
lymphatic endothelium and binding to HEVs is 71.8
 
  
 
11.3% (
 
n 
 
 
 
 4) of the adhesion in nonstatic conditions.
Static conditions obviously seem to bypass the need of se-
lectin-mediated interaction between lymphocytes and
HEVs, because L-selectin positive and negative lympho-
cytes bind equally wellx to HEV in static conditions (L-se-
lectin negative cells bound 1.04
 
   
 
0.04 times better than
L-selectin positive lymphocytes, 
 
n
 
 
 
 
 
 2). In contrast, under
rotatory conditions L-selectin negative cells bind approxi-
mately three times less efficiently to peripheral lymph
node HEVs than unseparated peripheral blood lympho-
cytes (17).
Using the static assay lymphocyte binding to endothe-
lium in lymphatic sinuses on frozen sections of lymph
nodes could be measured (Fig. 2 A–C). Lymphatic sinuses
are the sites where lymphocytes exit from the organized
lymphatic areas of the lymph node and thus belong to the
efferent lymphatic system. Although the isolated peripheral
blood mononuclear cell population used in the assays con-
tains a small fraction of monocytes, (easily recognizable by
their ruffle appearance under dark field microscopy) they
do not seem to bind to lymphatic endothelium. To test the
efficiency of binding of T cell subtypes to lymphatic endo-
thelium we stained the lymphocytes with PE-conjugated
anti-CD4 and CD8 antibodies before the assays. CD4 and
CD8 T cells had almost equal capacity to bind to lymphatic
endothelium, because the percentages of bound CD8 and
CD4 positive cells were almost the same as in the input
population (CD4 cells bound 1.1
 
   
 
0.1 times better than
CD8 cells, 
 
n 
 
 
 
 4).
When the lymph node sections were pre-treated with
3-155 antibody lymphocyte binding to lymphatic endothe-
lium was reduced by 45% (Fig. 2 D). Moreover, inhibition
of the binding was dependent on the concentration of the
antibody used (Fig. 2 E). These data indicate that the mole-
cule recognized by 3-155 on lymphatic vessels indeed me-
diates lymphocyte binding. 
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The Molecule Detected by 3-155 mAb Is MR or its Close
Homologue.
 
We purified 3-155 protein using affinity
chromatography. After cleavage with trypsin, mass spectro-
metric analyses yielded 16 peptides that had identical se-
quences with MR. These sequences covered altogether
182 amino acids (12% of the 1,456 amino acids of MR)
and spanned practically the entire length of the molecule
(the amino acids between 24 and 1,285). These results sug-
gested that either the molecule recognized by 3-155 is MR
or its close homologue. No identical sequences were found
in the other known members of the MR family (phospho-
lipase A2 receptor, reference 18; DEC-205, reference 19;
and a novel lectin, reference 20).
To further study the identity of the antigen recognized
by 3-155 with MR, crossprecipitations were performed.
Beads coupled to 3-155 and commercial anti-MR antibody
Figure 1. The monoclonal an-
tibody 3-155 recognizes lym-
phatic endothelium both in af-
ferent and efferent lymphatic
systems. In indirect immunoper-
oxidase staining the afferent lym-
phatic sacs (arrowheads) in the
skin stain positively (epidermis
pointed out by an arrow). Some
of the positive structures are cells
belonging to macrophage lin-
eage. (A) The staining with a
negative control antibody does
not show any specific reactivity
(B). 3-155 reacts with small lym-
phatic vessels (cross-sectional
profile, arrows), and with larger
sinusoids (a single endothelial
cell layer is seen, arrowhead) in
the lymph node (C). The same
area lacks any reactivity when
stained with a negative control
antibody (D). (E) The inset dem-
onstrates expression of 3-155 an-
tigen in sinusoidal endothelium
with a high power magnification.
In other organs studied sinusoi-
dal endothelium of liver, occa-
sional tissue macrophages, and
lymphatic vessels stained posi-
tively with 3-155 (data not
shown). Double stainings of
lymphatic vessels in a lymph
node (F–I) and skin (J–M) with
3-155, anti–VEGFR-3, and neg-
ative control antibodies (I and
M). Two-color staining of
lymph node sections with 3-155
(green), MECA-79 (against
PNAd; red) (N) and negative
control antibodies (O). The op-
posite phenotypes of lymphatic
endothelium and HEVs regard-
ing expression of MR and
PNAds are obvious. Arrows
point to the lymphatic endothe-
lium (F, G, H, J, K, L, and N)
and an arrowhead to HEVs (N). 
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were both able to deplete MR from the lysate although the
beads coupled to a negative control antibody were not able
to do so (Fig. 3 A). The characteristic feature of MR is its
inducibility on activated monocytes. As can be seen in Fig.
3 B, 3-155 reacted positively with activated blood mono-
cytes and gave practically an identical staining pattern with
a known anti-MR antibody. Lymphocytes from blood and
thoracic duct were negative with both antibodies (data not
shown). These results strongly suggest that 3-155 antigen is
indeed a MR.
 
Lymphatic MR Has Indistinguishable Molecular Mass and
Glycosylation with Macrophage MR.
 
Because the cDNA en-
coding MR can produce molecules with different binding
specificities even in the same cell type (21), we next ana-
lyzed whether MR on macrophages and lymphatic endo-
thelium are similar regarding their molecular mass and gly-
cosylation. We treated lysates from activated monocytes
and lymph nodes with different glycosidases. The molecu-
lar masses of macrophage and lymphatic MRs were practi-
cally identical after neuraminidase (removes sialic acids),
 
O
 
-glycanase (cleaves off 
 
O
 
-linked carbohydrates), and 
 
N
 
-gly-
canase (cuts off 
 
N
 
-linked carbohydrates) digestions (Fig. 3
C). This indicates that lymph node MR that almost en-
tirely originates from lymphoid endothelium (Fig. 1 C) is
structurally very similar if not identical to macrophage MR.
 
L-selectin Is a Lymphocyte Counter-Receptor of Lymphatic
MR.
 
Mouse L-selectin chimera produced in silk worm
cells has been reported to have affinity towards MR.
However, due to absence of MR on HEVs, this interac-
tion has been considered as an artefact resulting from the
baculovirus expression system (22). Because MR on lym-
phatic endothelium unambiguously was involved in lym-
phocyte binding we tested whether a function-blocking
anti–L-selectin antibody Dreg-56 is able to inhibit lym-
phocyte binding to lymphatic endothelium. In these stud-
ies blocking of L-selectin diminished lymphocyte adhesion
by 59%. Simultaneous blocking of L-selectin and lym-
phatic MR did not show any additive inhibition strongly
suggesting that both molecules are mediating the adhesion
of the same cell population and perhaps they even act as a
receptor ligand pair (Fig. 4 A). We also selected L-selectin
positive and negative lymphocytes and tested their capac-
Figure 2. The molecule recognized by 3-155 is involved in
lymphocyte binding to lymphatic endothelium. An adhesion
assay was performed to measure lymphocyte binding to lym-
phatic endothelium. In this assay the lymphocytes (some
pointed out by arrows) specifically bind to endothelium of
smaller lymphatic vessels that appear as bunches (A) or to en-
dothelial cells that are lining the larger sinusoids (B) (see stain-
ing in Fig. 1 C for comparison of these two types of lym-
phatic vessels). After incubating the sections with 3-155
antibody the number of bound cells is decreased. Two sinuses
with markedly decreased number of lymphocytes are indi-
cated by arrowheads (C). In D, the results of three indepen-
dent inhibition experiments with 3-155 hybridoma superna-
tant are shown as mean percentage of maximal binding  
SEM. (E) Concentration dependent-inhibition of 3-155. 
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ity to adhere to lymphatic endothelium. Both populations
showed comparable binding efficiency to lymphatic vessels
(binding of L-selectin negative cells was 98.4
 
   
 
7.6% that
of L-selectin positive cells) but only the binding of L-selec-
tin positive population could be significantly inhibited
with 3-155 anti-MR antibody (Fig. 4 B). Finally we used
an L-selectin-IgM chimera to test whether it can bind to
lymphatic endothelium in lymph nodes. In these experi-
ments, L-selectin-IgM chimera strongly bound to lym-
phatic endothelium as well as to HEVs, demonstrating the
presence of its ligand also in lymph vessels (Fig. 4 C and
D). Proof for direct binding between L-selectin-IgM and
lymphatic MR was obtained from depletion experiments.
When lymph node lysate was precleared with beads cou-
pled to L-selectin-IgM, the majority (77%) of MR con-
comitantly disappeared. In contrast, preclearing with the
control beads could not remove the MR (Fig. 4 F). To-
gether, these data strongly indicate that MR is a novel
ligand for L-selectin.
 
Discussion
 
MR has a well established role both in endocytotic
clearance of certain glycoproteins and in macrophage
phagocytosis of microorganisms (23). Presence of MR on
sinusoidal endothelial cells has been reported but its role
there has remained enigmatic (24, 25). Results of this work
reveal a novel role for lymphatic MR and represent the first
molecular identification of the system controlling lympho-
cyte exit from lymph nodes. Moreover, discovery of L-selec-
tin as a counter-receptor of lymphatic MR expands the
repertoire of L-selectin ligands.
Both MR and L-selectin contain lectin domains and rec-
ognize a wide variety of carbohydrates. Furthermore, they
both are heavily glycosylated themselves creating theoreti-
cal possibilities for different types of recognition events be-
tween these two molecules (26–30). However, the anti-
body Dreg-56 against L-selectin used in the inhibition
assays is reported to recognize a lectin domain of L-selectin
(31), strongly suggesting involvement of the lectin domain
Figure 3. 3-155 antigen is an MR and macrophage and lymphatic MR have
identical cell distribution and indistinguishable glycosylation profiles. (A) 3-155 an-
tibody coupled to Sepharose 4B beads via rabbit anti–mouse IgG as well as the pos-
itive control precipitation with the commercial anti-MR antibody (same as the de-
tecting antibody) were able to remove MR from lymphocyte lysate when tested by
immunoblotting using a commercial anti-MR antibody. After the negative control
precipitation with beads coupled to an irrelevant antibody (3G6) the MR band is
clearly visible. (B) Histograms from flow cytometric analyses demonstrate that
GM-CSF–activated monocytes show positive and identical staining both with a
known anti–human MR antibody ( -hMR) and 3-155. 3G6 is a negative control
antibody. (C) After various glycosidase treatments of activated monocyte (mac-
rophages) and lymph node lysates (lymphatic), molecules were separated by
SDS-PAGE and analyzed by immunoblotting with 3-155 and a negative control
antibody (3G6). 
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of L-selectin in the binding to a carbohydrate epitope on
MR. Theoretically, the possibility remains that a carbohy-
drate forms a link between the lectin domains of both
L-selectin and MR.
As L-selectin interacts with PNAds on HEVs and the
present data identifies MR as an L-selectin ligand on lym-
phatic endothelium, it may implicate that using these al-
ternative ligands L-selectin guides lymphocyte migration
at various steps of the recirculation cascade. Thus, first in
blood L-selectin directs lymphocyte trafficking to lymph
nodes by binding to PNAds on HEVs (4). Notably, this
interaction requires shear force over 0.6 dynes/cm
 
2
 
 that is
present in blood circulation at the entrance site of lym-
phocytes (32). Then during the activation step in the ad-
hesion cascade L-selectin is lost by proteolytic cleavage
 
(33, 34). However, lymphocytes regain L-selectin expres-
sion within the lymph node. Finally, under static condi-
tions L-selectin binds to MR on lymphatic endothelium.
Therefore, the recognition domains used by L-selectin on
HEVs (PNAd
 
 
 
, MR
 
 
 
) and on lymphatic endothelium
(having exactly the opposite phenotype PNAd
 
 
 
, MR
 
 
 
)
may be different. Although for technical reasons we were
able to test lymphocyte binding only to sinusoidal endo-
thelial cells, the presence of MR also in the afferent lym-
phatic vessels for example in the skin may indicate that
L-selectin plays a role in lymphocyte exit from nonlym-
phoid tissues as well.
We believe that the experimental conditions used in this
work closely reflect the situation in vivo. When lympho-
cytes are gathering into lymphatic sinusoids ready to leave
Figure 4. L-selectin is a counter-receptor of MR on lymphatic endothelium. (A) Frozen
section adhesion assays were performed by inhibiting lymphocyte binding to sinusoidal en-
dothelium with 3-155, Dreg-56 (anti–L-selectin), both antibodies together, or with a con-
trol antibody (anti–human HLA ABC). The results of four independent assays are shown
(mean percentage of maximal binding   SEM). (B) 3-155 significantly inhibits binding of
L-selectin positive cells to lymphatic endothelium. In contrast, only minor inhibition is seen
when the binding of L-selectin negative cells is tested. Results of three independent assays
are presented. L-selectin-IgM chimera was incubated on frozen section of a human lymph
node. It binds to sinusoidal endothelial cells (arrow, C) to HEVs (pointed out by arrows, D).
(E) Negative control. The L-selectin-IgM chimera coupled beads and control beads were
used to deplete lymph node lysate and the nonprecipitated molecules were analyzed using
immunoblotting and the monoclonal antibodies indicated (F). 
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the lymph node, practically no shear is present. Also lym-
phocyte binding to lymphatic endothelium in vitro re-
quires static conditions, because in the presence of shear
stress only occasional lymphocytes (not even enough to get
any meaningful numbers to count) were able to adhere to
lymphatic endothelium. In contrast, L-selectin–mediated
binding to PNAds at HEVs is shear dependent, because in
the absence of shear both L-selectin negative and positive
lymphocytes bind with equal efficiency to peripheral
lymph node HEVs, presumably by integrin-mediated
mechanisms not requiring the shear. In nonstatic condi-
tions, L-selectin positive cells bind at least three times bet-
ter to peripheral lymph node HEV than L-selectin negative
lymphocytes (17).
Interestingly, CD4- and CD8-positive T cells seem to
have almost equal capacity to bind to lymphatic endothe-
lium. This is in striking contrast to the entrance site, be-
cause CD8 positive cells bind 1.5–2.0 times better than
CD4
 
 
 
 cells to peripheral lymph node HEVs (35). The
better capacity of CD8 to enter the lymph nodes may
compensate their smaller number among blood lympho-
cytes and result in rather equal numbers of entering CD4
and CD8 cells. Comparable binding to lymphatic endo-
thelium may then allow these different subtypes to leave
the lymph nodes with equal efficiency. Although the cell
populations (Ficoll-purified mononuclear cells from blood)
used in our binding assays contains small number of
monocytes and they bind very efficiently to HEV-like
vessels at sites of inflammation such as for example in in-
flamed synovium (36) monocytes did not bind to lym-
phatic endothelium. This is well in line with in vivo situ-
ation, because monocytes are not found in the efferent
lymph in normal conditions (37).
In conclusion, based on our
 
 
 
in vitro findings we hy-
pothesize that L-selectin could be involved in both lym-
phocyte entrance to and exit from lymph nodes. We sug-
gest that L-selectin-MR interactions may be involved in
the exit phase of physiologic lymphocyte recirculation.
These may theoretically also be involved in the exit of
L-selectin–expressing malignant cells and thus the spread
of L-selectin positive tumors. However, in vivo experi-
ments will be required to elucidate the actual role of L-selec-
tin-MR interactions in lymphocyte exit from the lymph
nodes.
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